The speed of vaccine development

The speed of vaccine development


covid vaccine
Credit: Pixabay/CC0 Public Domain

Q: How can I be expected to trust the safety of the COVID-19 vaccine when it was developed so rapidly?

A: We hear this question frequently, and we can understand how it may seem like the development of the vaccine was quick.

The speed was a result of many pharmaceutical companies simultaneously investing significant resources into quickly developing a vaccine because of the world-wide impact of the pandemic. The emergency situation warranted an emergency response, but that does not mean that companies bypassed safety protocols or adequate testing.

“Mayo Clinic only ever recommends the use of vaccines that we are confident are safe,” says Martin Herrmann, M.D., medical director of Mayo Clinic Health System in Waseca and New Prague.

Take the development of the Pfizer vaccine, for example. This vaccine developed by Pfizer/BioNTech was initially studied in approximately 43,000 people.

To receive emergency use authorization, the biopharmaceutical manufacturer must have followed at least half of the study participants for at least two months after completing the vaccination series, and the vaccine must be proven safe and effective in that population.

In addition to the safety review by the FDA, the Advisory Committee on Immunization convened a panel of vaccine safety experts to independently evaluate the safety data from the clinical trial. Mayo Clinic vaccine experts also reviewed the available data.

The safety of COVID-19 vaccines will continue to be closely monitored by the Centers for Disease Control and Prevention (CDC) and the FDA.


COVID-19 vaccine for younger kids a step closer


©2021 Mayo Clinic News Network. Distributed by Tribune Content Agency, LLC.

Citation:
COVID queries: The speed of vaccine development (2021, October 7)
retrieved 8 October 2021
from https://medicalxpress.com/news/2021-10-covid-queries-vaccine.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.





https://medicalxpress.com/news/2021-10-covid-queries-vaccine.html